TTP-3 is an asymmetric Ugi-derived ionizable lipid developed specifically for pulmonary delivery of structured suppressor tRNA cargo. Its architecture combines a dimethylaminopropyl ionizable headgroup, two amide-containing linkages, and chemically distinct hydrophobic tails. Selected from a 1,000-member lipid library, TTP-3 showed the strongest suppressor-tRNA delivery in a cystic-fibrosis-relevant air–liquid interface model containing artificial mucus. An optimized formulation containing TTP-3, DOPE, β-sitosterol, and C14-PEG2000 produced approximately 38-fold higher functional pulmonary reporter expression than MC3 following intratracheal administration in mice. TTP-3 LNPs preferentially delivered tRNA to airway epithelial cells, including ciliated, club, ionocyte, and basal progenitor populations. When combined with chemically modified suppressor tRNAs, the platform restored CFTR expression and function in cellular, mouse, and patient-derived organoid models. TTP-3 remains a preclinical research lipid, and further optimization is required for aerosol delivery, repeat dosing, and clinical translation.

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.